BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hyrich KL, Verstappen SM. Biologic therapies and pregnancy: the story so far. Rheumatology (Oxford). 2014;53:1377-1385. [PMID: 24352337 DOI: 10.1093/rheumatology/ket409] [Cited by in Crossref: 73] [Cited by in F6Publishing: 59] [Article Influence: 9.1] [Reference Citation Analysis]
Number Citing Articles
1 Rademaker M, Agnew K, Andrews M, Armour K, Baker C, Foley P, Frew J, Gebauer K, Gupta M, Kennedy D, Marshman G, Sullivan J. Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian Psoriasis Collaboration. Australas J Dermatol 2018;59:86-100. [PMID: 28543445 DOI: 10.1111/ajd.12641] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 7.8] [Reference Citation Analysis]
2 Mariette X, Förger F, Abraham B, Flynn AD, Moltó A, Flipo RM, van Tubergen A, Shaughnessy L, Simpson J, Teil M, Helmer E, Wang M, Chakravarty EF. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis 2018;77:228-33. [PMID: 29030361 DOI: 10.1136/annrheumdis-2017-212196] [Cited by in Crossref: 140] [Cited by in F6Publishing: 107] [Article Influence: 35.0] [Reference Citation Analysis]
3 Salat D, Llop R, Aguilera C, Danés I, Bosch M, Asensio C, Castañeda F, Esterlich E, Vallano A. Therapeutic enquiries about biological agents as a tool to identify safety aspects and patterns of use. Eur J Hosp Pharm 2016;23:161-5. [PMID: 31156839 DOI: 10.1136/ejhpharm-2015-000770] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
4 Keeling SO, Bowker SL, Savu A, Kaul P. A Population-level Analysis of the Differing Effects of Rheumatoid Arthritis and Spondyloarthritis on Peripartum Outcomes. J Rheumatol 2020;47:197-203. [PMID: 31043549 DOI: 10.3899/jrheum.181320] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
5 Grunewald S, Jank A. New systemic agents in dermatology with respect to fertility, pregnancy, and lactation. J Dtsch Dermatol Ges 2015;13:277-89; quiz 290. [PMID: 25819232 DOI: 10.1111/ddg.12596] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
6 Colla L, Diena D, Rossetti M, Manzione AM, Marozio L, Benedetto C, Biancone L. Immunosuppression in pregnant women with renal disease: review of the latest evidence in the biologics era. J Nephrol 2018;31:361-83. [DOI: 10.1007/s40620-018-0477-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
7 Conigliaro P, Triggianese P, De Martino E, Fonti GL, Chimenti MS, Sunzini F, Viola A, Canofari C, Perricone R. Challenges in the treatment of Rheumatoid Arthritis. Autoimmun Rev 2019;18:706-13. [PMID: 31059844 DOI: 10.1016/j.autrev.2019.05.007] [Cited by in Crossref: 56] [Cited by in F6Publishing: 45] [Article Influence: 28.0] [Reference Citation Analysis]
8 Romano C, Esposito S, Ferrara R, Cuomo G. Tailoring biologic therapy for real-world rheumatoid arthritis patients. Expert Opin Biol Ther 2021;21:661-74. [PMID: 33147106 DOI: 10.1080/14712598.2021.1847268] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Fattah A, Asadi A, Shayesteh MRH, Hesari FH, Jamalzehi S, Abbasi M, Mousavi MJ, Aslani S. Fertility and infertility implications in rheumatoid arthritis; state of the art. Inflamm Res 2020;69:721-9. [PMID: 32458007 DOI: 10.1007/s00011-020-01362-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Hladunewich MA, Bramham K, Jim B, Maynard S. Managing glomerular disease in pregnancy. Nephrology Dialysis Transplantation 2017;32:i48-56. [DOI: 10.1093/ndt/gfw319] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
11 Ince-Askan H, Hazes JMW, Dolhain RJEM. Identifying Clinical Factors Associated With Low Disease Activity and Remission of Rheumatoid Arthritis During Pregnancy. Arthritis Care Res (Hoboken) 2017;69:1297-303. [PMID: 27813290 DOI: 10.1002/acr.23143] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
12 Vena GA, Cassano N, Bellia G, Colombo D. Psoriasis in pregnancy: challenges and solutions. Psoriasis (Auckl) 2015;5:83-95. [PMID: 29387585 DOI: 10.2147/PTT.S82975] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
13 Van Laer M, Penaloza A, Stockman W, Meert P, Lambert C, Hermans C. Compartment syndrome of the forearm with life-threatening bleeding after fasciotomy as the presenting sign of postpartum acquired hemophilia A: a case report. Blood Coagul Fibrinolysis 2019;30:120-6. [PMID: 30864964 DOI: 10.1097/MBC.0000000000000799] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Grunewald S, Staubach P. Dermatologische topische und Systemtherapie in der Schwangerschaft. Hautarzt 2017;68:127-35. [DOI: 10.1007/s00105-016-3921-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
15 Webster P, Nelson-Piercy C, Lightstone L. A complicated multisystem flare of systemic lupus erythematosus during pregnancy. BMJ Case Rep 2017;2017:bcr2016217546. [PMID: 28179384 DOI: 10.1136/bcr-2016-217546] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Thomas MR, Robinson S, Scully MA. How we manage thrombotic microangiopathies in pregnancy. Br J Haematol 2016;173:821-30. [DOI: 10.1111/bjh.14045] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
17 Harman K, Brown D, Exton L, Groves R, Hampton P, Mohd Mustapa M, Setterfield J, Yesudian P, Mchenry P, Gibbon K, Buckley D, Leslie T, Mallon E, Wakelin S, Ungureanu S, Hunasehally R, Cork M, Johnston G, Natkunarajah J, Worsnop F, Chiang N, Duarte Williamson C, Donnelly J, Saunders C, Brain A. British Association of Dermatologists’ guidelines for the management of pemphigus vulgaris 2017. Br J Dermatol 2017;177:1170-201. [DOI: 10.1111/bjd.15930] [Cited by in Crossref: 72] [Cited by in F6Publishing: 46] [Article Influence: 18.0] [Reference Citation Analysis]
18 Barg AA, Livnat T, Kenet G. An extra X does not prevent acquired hemophilia – Pregnancy-associated acquired hemophilia A. Thrombosis Research 2017;151:S82-5. [DOI: 10.1016/s0049-3848(17)30074-9] [Cited by in Crossref: 5] [Article Influence: 1.3] [Reference Citation Analysis]
19 Alijotas-reig J, Esteve-valverde E, Ferrer-oliveras R. Tratamiento de las gestantes con enfermedades reumáticas o autoinmunitarias sistémicas con fármacos inmunodepresores y biológicos. Medicina Clínica 2016;147:352-60. [DOI: 10.1016/j.medcli.2016.05.020] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
20 Owczarek W, Walecka I, Lesiak A, Czajkowski R, Reich A, Zerda I, Narbutt J. The use of biological drugs in psoriasis patients prior to pregnancy, during pregnancy and lactation: a review of current clinical guidelines. Postepy Dermatol Alergol 2020;37:821-30. [PMID: 33603597 DOI: 10.5114/ada.2020.102089] [Reference Citation Analysis]
21 Chebli JM, Gaburri PD, Chebli LA, da Rocha Ribeiro TC, Pinto AL, Ambrogini Júnior O, Damião AO. A guide to prepare patients with inflammatory bowel diseases for anti-TNF-α therapy. Med Sci Monit 2014;20:487-98. [PMID: 24667275 DOI: 10.12659/MSM.890331] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 2.9] [Reference Citation Analysis]
22 Ferreira C, Azevedo A, Nogueira M, Torres T. Management of psoriasis in pregnancy - a review of the evidence to date. Drugs Context 2020;9:2019-11-6. [PMID: 32201494 DOI: 10.7573/dic.2019-11-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
23 Moroni G, Ponticelli C. Pregnancy in women with systemic lupus erythematosus (SLE). European Journal of Internal Medicine 2016;32:7-12. [DOI: 10.1016/j.ejim.2016.04.005] [Cited by in Crossref: 31] [Cited by in F6Publishing: 21] [Article Influence: 6.2] [Reference Citation Analysis]
24 Takeuchi S, Kamata M, Uchida H, Nagata M, Fukaya S, Hayashi K, Fukuyasu A, Tanaka T, Ishikawa T, Ohnishi T, Tada Y. Serum infliximab level in an infant delivered from a mother with psoriatic arthritis receiving infliximab. J Dermatol 2020;47:e28-9. [PMID: 31621097 DOI: 10.1111/1346-8138.15124] [Reference Citation Analysis]
25 Tosounidou S, Gordon C. Medications in pregnancy and breastfeeding. Best Practice & Research Clinical Obstetrics & Gynaecology 2020;64:68-76. [DOI: 10.1016/j.bpobgyn.2019.10.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
26 Webster P, Lightstone L, McKay DB, Josephson MA. Pregnancy in chronic kidney disease and kidney transplantation. Kidney Int. 2017;91:1047-1056. [PMID: 28209334 DOI: 10.1016/j.kint.2016.10.045] [Cited by in Crossref: 56] [Cited by in F6Publishing: 43] [Article Influence: 14.0] [Reference Citation Analysis]
27 Romano C, Esposito S, Ferrara R, Cuomo G. Choosing the most appropriate biologic therapy for Crohn’s disease according to concomitant extra-intestinal manifestations, comorbidities, or physiologic conditions. Expert Opinion on Biological Therapy 2020;20:49-62. [DOI: 10.1080/14712598.2020.1689953] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
28 Perng P, Zampella JG, Okoye GA. Management of hidradenitis suppurativa in pregnancy. Journal of the American Academy of Dermatology 2017;76:979-89. [DOI: 10.1016/j.jaad.2016.10.032] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
29 Ince-Askan H, Dolhain RJ. Pregnancy and rheumatoid arthritis. Best Pract Res Clin Rheumatol 2015;29:580-96. [PMID: 26697768 DOI: 10.1016/j.berh.2015.07.001] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
30 Garip Y. Use of biologic agents for rheumatic diseases in pregnancy. World J Rheumatol 2015; 5(2): 50-58 [DOI: 10.5499/wjr.v5.i2.50] [Reference Citation Analysis]
31 Mesquida M, Leszczynska A, Llorenç V, Adán A. Interleukin-6 blockade in ocular inflammatory diseases. Clin Exp Immunol 2014;176:301-9. [PMID: 24528300 DOI: 10.1111/cei.12295] [Cited by in Crossref: 57] [Cited by in F6Publishing: 57] [Article Influence: 8.1] [Reference Citation Analysis]
32 Ackerman IN, Ngian G, Van Doornum S, Briggs AM. A systematic review of interventions to improve knowledge and self-management skills concerning contraception, pregnancy and breastfeeding in people with rheumatoid arthritis. Clin Rheumatol 2016;35:33-41. [DOI: 10.1007/s10067-015-3131-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
33 Leroy C, Rigot JM, Leroy M, Decanter C, Le Mapihan K, Parent AS, Le Guillou AC, Yakoub-Agha I, Dharancy S, Noel C, Vantyghem MC. Immunosuppressive drugs and fertility. Orphanet J Rare Dis 2015;10:136. [PMID: 26490561 DOI: 10.1186/s13023-015-0332-8] [Cited by in Crossref: 84] [Cited by in F6Publishing: 72] [Article Influence: 14.0] [Reference Citation Analysis]
34 Soh MC, Nelson-piercy C. High-risk pregnancy and the rheumatologist. Rheumatology 2015;54:572-87. [DOI: 10.1093/rheumatology/keu394] [Cited by in Crossref: 48] [Cited by in F6Publishing: 32] [Article Influence: 6.9] [Reference Citation Analysis]
35 Yamamoto Y, Aoki S. Systemic lupus erythematosus: strategies to improve pregnancy outcomes. Int J Womens Health 2016;8:265-72. [PMID: 27468250 DOI: 10.2147/IJWH.S90157] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 2.6] [Reference Citation Analysis]
36 Taraborelli M, Erkan D. Pregnancy-Related Challenges in Systemic Autoimmune Diseases. J Infus Nurs 2015;38:360-8. [PMID: 26339942 DOI: 10.1097/NAN.0000000000000124] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
37 Molinelli E, Sapigni C, Campanati A, Brisigotti V, Offidani A. Metabolic, pharmacokinetic, and toxicological issues of biologic therapies currently used in the treatment of hidradenitis suppurativa. Expert Opin Drug Metab Toxicol 2020;16:1019-37. [PMID: 32896186 DOI: 10.1080/17425255.2020.1810233] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Hoxha A, Calligaro A, Di Poi E, Peccatori S, Favaro M, Del Ross T, Ramonda R, Grava C, Raffeiner B, Ravagni P, De Vita S, Ruffatti A. Pregnancy and foetal outcomes following anti-tumor necrosis factor alpha therapy: A prospective multicentre study. Joint Bone Spine 2017;84:169-73. [DOI: 10.1016/j.jbspin.2016.03.014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
39 Eliesen GAM, van Drongelen J, van Hove H, Kooijman NI, van den Broek P, de Vries A, Roeleveld N, Russel FGM, Greupink R. Assessment of Placental Disposition of Infliximab and Etanercept in Women With Autoimmune Diseases and in the Ex Vivo Perfused Placenta. Clin Pharmacol Ther 2020;108:99-106. [PMID: 32153014 DOI: 10.1002/cpt.1827] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
40 Biancone L, Annese V, Ardizzone S, Armuzzi A, Calabrese E, Caprioli F, Castiglione F, Comberlato M, Cottone M, Danese S, Daperno M, D’incà R, Frieri G, Fries W, Gionchetti P, Kohn A, Latella G, Milla M, Orlando A, Papi C, Petruzziello C, Riegler G, Rizzello F, Saibeni S, Scribano ML, Vecchi M, Vernia P, Meucci G, Aratari A, Bossa F, Cappello M, Cassinotti A, Chiriatti A, Fiorino G, Formica V, Guidi L, Losco A, Mocciaro F, Onali S, Pastorelli L, Pica R, Principi M, Renna S, Ricci C, Rispo A, Rogai F, Sarmati L, Scaldaferri F, Spina L, Tambasco R, Testa A, Viscido A. Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease 2017;49:338-58. [DOI: 10.1016/j.dld.2017.01.141] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 6.5] [Reference Citation Analysis]
41 Hyrich KL. Assessing the safety of new drugs during pregnancy. Br J Dermatol 2018;178:18-9. [PMID: 29357613 DOI: 10.1111/bjd.16057] [Reference Citation Analysis]
42 Nakajima K, Watanabe O, Mochizuki M, Nakasone A, Ishizuka N, Murashima A. Pregnancy outcomes after exposure to tocilizumab: A retrospective analysis of 61 patients in Japan. Mod Rheumatol 2016;26:667-71. [PMID: 26873562 DOI: 10.3109/14397595.2016.1147405] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 9.4] [Reference Citation Analysis]
43 Merola JF, Lockshin B, Mody EA. Switching biologics in the treatment of psoriatic arthritis. Seminars in Arthritis and Rheumatism 2017;47:29-37. [DOI: 10.1016/j.semarthrit.2017.02.001] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 11.0] [Reference Citation Analysis]
44 Hoeltzenbein M, Beck E, Rajwanshi R, Gøtestam Skorpen C, Berber E, Schaefer C, Østensen M. Tocilizumab use in pregnancy: Analysis of a global safety database including data from clinical trials and post-marketing data. Seminars in Arthritis and Rheumatism 2016;46:238-45. [DOI: 10.1016/j.semarthrit.2016.05.004] [Cited by in Crossref: 64] [Cited by in F6Publishing: 57] [Article Influence: 12.8] [Reference Citation Analysis]
45 Soh MC, Moretto M. The use of biologics for autoimmune rheumatic diseases in fertility and pregnancy. Obstet Med 2020;13:5-13. [PMID: 32284726 DOI: 10.1177/1753495X19841799] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
46 Smeraglia J, Silva JP, Jones K. Improving the sensitivity and specificity of a bioanalytical assay for the measurement of certolizumab pegol. Bioanalysis 2017;9:1217-26. [PMID: 28705025 DOI: 10.4155/bio-2017-0124] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
47 de Jong PH, Dolhain RJ. Fertility, Pregnancy, and Lactation in Rheumatoid Arthritis. Rheum Dis Clin North Am 2017;43:227-37. [PMID: 28390565 DOI: 10.1016/j.rdc.2016.12.004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
48 Ostensen M. Safety issues of biologics in pregnant patients with rheumatic diseases. Ann N Y Acad Sci. 2014;1317:32-38. [PMID: 24840548 DOI: 10.1111/nyas.12456] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 4.9] [Reference Citation Analysis]
49 Felquer ML, Soriano ER. New treatment paradigms in psoriatic arthritis: an update on new therapeutics approved by the U.S. Food and Drug Administration. Curr Opin Rheumatol 2015;27:99-106. [PMID: 25633241 DOI: 10.1097/BOR.0000000000000151] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
50 Ternant D, Bejan-Angoulvant T, Passot C, Mulleman D, Paintaud G. Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis. Clin Pharmacokinet 2015;54:1107-23. [PMID: 26123705 DOI: 10.1007/s40262-015-0296-9] [Cited by in Crossref: 63] [Cited by in F6Publishing: 54] [Article Influence: 12.6] [Reference Citation Analysis]
51 Alijotas-reig J, Esteve-valverde E, Ferrer-oliveras R, Llurba E, Gris JM. Tumor Necrosis Factor-Alpha and Pregnancy: Focus on Biologics. An Updated and Comprehensive Review. Clinic Rev Allerg Immunol 2017;53:40-53. [DOI: 10.1007/s12016-016-8596-x] [Cited by in Crossref: 70] [Cited by in F6Publishing: 65] [Article Influence: 17.5] [Reference Citation Analysis]
52 Carman WJ, Accortt NA, Anthony MS, Iles J, Enger C. Pregnancy and infant outcomes including major congenital malformations among women with chronic inflammatory arthritis or psoriasis, with and without etanercept use. Pharmacoepidemiol Drug Saf 2017;26:1109-18. [PMID: 28758274 DOI: 10.1002/pds.4261] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
53 Dewarrat N, Gavillet M, Angelillo-Scherrer A, Naveiras O, Grandoni F, Tsakiris DA, Alberio L, Blum S. Acquired haemophilia A in the postpartum and risk of relapse in subsequent pregnancies: A systematic literature review. Haemophilia 2021;27:199-210. [PMID: 33550699 DOI: 10.1111/hae.14233] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Koryürek ÖM, Kalkan G. A new alternative therapy in dermatology: tocilizumab. Cutaneous and Ocular Toxicology 2016. [DOI: 10.3109/15569527.2015.1049356] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
55 Louthrenoo W, Kasitanon N, Katchamart W, Aiewruengsurat D, Chevaisrakul P, Chiowchanwisawakit P, Dechanuwong P, Hanvivadhanakul P, Mahakkanukrauh A, Manavathongchai S, Muangchan C, Narongroeknawin P, Phumethum V, Siripaitoon B, Suesuwan A, Suwannaroj S, Uea-areewongsa P, Ukritchon S, Asavatanabodee P, Koolvisoot A, Nanagara R, Totemchokchyakarn K, Nuntirooj K, Kitumnuaypong T. 2016 updated Thai Rheumatism Association Recommendations for the use of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis. Int J Rheum Dis 2017;20:1166-84. [DOI: 10.1111/1756-185x.13130] [Cited by in Crossref: 5] [Article Influence: 1.3] [Reference Citation Analysis]
56 Aw J, Griffiths H, Zochling J, Lanzafame A, Jordan A. Usability of the Certolizumab Pegol Auto-Injection Device in Australian Patients with Chronic Rheumatic Diseases: Results from a Market Research Study. Patient Prefer Adherence 2021;15:1469-76. [PMID: 34234420 DOI: 10.2147/PPA.S310086] [Reference Citation Analysis]
57 Ciplea AI, Hellwig K. Exposure to natalizumab during pregnancy and lactation is safe - Commentary. Mult Scler 2020;26:892-3. [PMID: 32508210 DOI: 10.1177/1352458520928795] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
58 Kumar M, Ray L, Vemuri S, Simon TA. Pregnancy outcomes following exposure to abatacept during pregnancy. Seminars in Arthritis and Rheumatism 2015;45:351-6. [DOI: 10.1016/j.semarthrit.2015.06.016] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 5.7] [Reference Citation Analysis]
59 Giles I, Yee C, Gordon C. Stratifying management of rheumatic disease for pregnancy and breastfeeding. Nat Rev Rheumatol 2019;15:391-402. [DOI: 10.1038/s41584-019-0240-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]